Bradbury Daniel 的 Form 4/A 修正申報
修正Castle Biosciences Inc（CSTL），2022/6/13 申報
- 申報編號
- 0001447362-22-000111
- 申報時間
- 2022/6/13
- 交易日
- 2022/1/4
- 申報延遲
- 160 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
- 原始申報日
- 2022/1/6
這份申報列了 3 筆非衍生性交易。沿用原件裡沒有重述的 6 筆交易。公開市場賣出合計 $158.9 萬。交易後 160 天申報。
這份修正申報重述了 0001447362-22-000007（2022/1/6 申報）的一部分，沒有重述的交易仍然有效，列在下面。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Bradbury DanielCIK 0001236397 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
沿用原件的交易
這份修正申報只重述了原件的一部分。原件其他的交易仍然有效，網站的交易表把它們算在這份修正申報底下。
來自 0001447362-22-000007（2022/1/6 申報）。
非衍生性證券（表 I）
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2022/1/4 | Common Stock | S賣出處分 | −4,618 | $43.50F7 | −$200,883 | 130,687 | 間接 | |
| 2022/1/5 | Common Stock | S賣出處分 | −2,763 | $43.21F9 | −$119,389.23 | 236,113 | 間接 | |
| 2022/1/5 | Common Stock | S賣出處分 | −4,840 | $43.64F10 | −$211,217.6 | 231,273 | 間接 | |
| 2022/1/5 | Common Stock | S賣出處分 | −4,375 | $40.44F11 | −$176,925 | 126,287 | 間接 | |
| 2022/1/5 | Common Stock | S賣出處分 | −2,477 | $41.04F12 | −$101,656.08 | 128,210 | 間接 | |
| 2022/1/5 | Common Stock | S賣出處分 | −1,898 | $42.09F13 | −$79,886.82 | 126,312 | 間接 |
原件的附註
這幾筆交易的價格在原件上引用的附註。
- F7
This transaction was executed in multiple trades at prices ranging from $43.305 to $43.770, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
表 I 有 1 筆交易的價格引用這則附註。
- F9
This transaction was executed in multiple trades at prices ranging from $42.470 to $43.460, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
表 I 有 1 筆交易的價格引用這則附註。
- F10
This transaction was executed in multiple trades at prices ranging from $43.470 to $44.150, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
表 I 有 1 筆交易的價格引用這則附註。
- F11
This transaction was executed in multiple trades at prices ranging from $40.280 to $40.670, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
表 I 有 1 筆交易的價格引用這則附註。
- F12
This transaction was executed in multiple trades at prices ranging from $40.670 to $41.660, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
表 I 有 1 筆交易的價格引用這則附註。
- F13
This transaction was executed in multiple trades at prices ranging from $41.820 to $42.470, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
表 I 有 1 筆交易的價格引用這則附註。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021.
- F2
This transaction was executed in multiple trades at prices ranging from $43.750 to $44.305, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
表 I 有 1 筆交易的價格引用這則附註。
- F3
Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares.
- F4
This transaction was executed in multiple trades at prices ranging from $42.695 to $43.300, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
表 I 有 1 筆交易的價格引用這則附註。
- F5
Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries.
- F6
This transaction was executed in multiple trades at prices ranging from $43.300 to $43.750, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
表 I 有 1 筆交易的價格引用這則附註。
- F7
Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries.
備註
This amendment is being filed to correct certain clerical errors in lines 1, 3 and 4 of Table I included in the Form 4 originally filed by the Reporting Person on January 6, 2022. This amendment corrects the allocation of shares sold on January 4, 2022, the weighted average sale prices and the range of sale prices for each transaction.